We have located links that may give you full text access.
Clinically important potential drug-drug interactions in outpatient settings.
Research in Social & Administrative Pharmacy : RSAP 2007 December
BACKGROUND: Although many potential drug-drug interactions (DDIs) are discussed in the clinical literature, only limited numbers of these are clinically important. Little is known about prescribing of agents involved in these clinically important DDIs at the national level.
OBJECTIVE: This study examined concomitant prescribing of drug combinations that have potential for clinically important DDIs in outpatient settings in the United States.
METHODS: The 2000-2002 National Ambulatory Medical Care Survey and the outpatient department portion of the 2000-2002 National Hospital Ambulatory Medical Care Survey were used to examine 25 clinically important DDIs that are most likely to harm patients if not detected. Descriptive statistics were used to characterize clinically important DDIs, whereas logistic regression analysis was applied to outpatient visits to examine patients at risk for clinically important DDIs.
RESULTS: An estimated 0.63% (95% confidence interval, 0.51-0.75) of outpatient visits involving 2 or more medications resulted in prescription combinations with potential for clinically important DDIs for an annual visit estimate of 2.26 million, or annual visit rate of 8.12 visits per 1000 persons. Fourteen of the 25 prescription combinations with potential for clinically important DDIs were prescribed in outpatient settings, with warfarin accounting for many of the visits that yielded the prescribing of interacting medications. A majority (82%) of the prescriptions for potentially interacting medications occurred in visits involving 5 or more medications. The study found that patients over 44 years of age, especially elderly, Medicare beneficiaries, and those prescribed multiple medications are at risk for receiving prescription combinations with potential for a clinically important DDI.
CONCLUSIONS: Although a small percentage of outpatient visits resulted in prescription combinations with potential for clinically important DDIs, these interactions can have significant implications due to medication-related morbidity and mortality. Pharmacists can play a critical role in managing the medication therapy of patients at risk for clinically important DDIs. Further research is needed to evaluate the economic, clinical, and humanistic outcomes of clinically important DDIs, especially among those at risk.
OBJECTIVE: This study examined concomitant prescribing of drug combinations that have potential for clinically important DDIs in outpatient settings in the United States.
METHODS: The 2000-2002 National Ambulatory Medical Care Survey and the outpatient department portion of the 2000-2002 National Hospital Ambulatory Medical Care Survey were used to examine 25 clinically important DDIs that are most likely to harm patients if not detected. Descriptive statistics were used to characterize clinically important DDIs, whereas logistic regression analysis was applied to outpatient visits to examine patients at risk for clinically important DDIs.
RESULTS: An estimated 0.63% (95% confidence interval, 0.51-0.75) of outpatient visits involving 2 or more medications resulted in prescription combinations with potential for clinically important DDIs for an annual visit estimate of 2.26 million, or annual visit rate of 8.12 visits per 1000 persons. Fourteen of the 25 prescription combinations with potential for clinically important DDIs were prescribed in outpatient settings, with warfarin accounting for many of the visits that yielded the prescribing of interacting medications. A majority (82%) of the prescriptions for potentially interacting medications occurred in visits involving 5 or more medications. The study found that patients over 44 years of age, especially elderly, Medicare beneficiaries, and those prescribed multiple medications are at risk for receiving prescription combinations with potential for a clinically important DDI.
CONCLUSIONS: Although a small percentage of outpatient visits resulted in prescription combinations with potential for clinically important DDIs, these interactions can have significant implications due to medication-related morbidity and mortality. Pharmacists can play a critical role in managing the medication therapy of patients at risk for clinically important DDIs. Further research is needed to evaluate the economic, clinical, and humanistic outcomes of clinically important DDIs, especially among those at risk.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app